(Q35879252)

10 August 2017

Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus (English)

1 reference

10 August 2017

1 reference

1 reference

6

Nobuo Yaegashi

1 reference

10 August 2017

4

Hitoshi Niikura

1 reference

10 August 2017

2

Jun-Ichi Akahira

1 reference

10 August 2017

7

Toru Tase

1 reference

10 August 2017

1

Masafumi Toyoshima

1 reference

10 August 2017

Gen Matsunaga

3

1 reference

PubMed ID

15350372

10 August 2017

Kiyoshi Ito

series ordinal

5

1 reference

PubMed ID

15350372

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

10 August 2017

1 reference

10 August 2017

94

1 reference

10 August 2017

3

1 reference

10 August 2017

774-778

1 reference

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Treatment options for endometrial cancer: experience with topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Prolonged remission of endometrial cancer with paclitaxel and carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.048

10.1016/J.YGYNO.2004.05.048

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15350372